Status:
COMPLETED
Microbiota and Probiotic Therapy in Ulcerative Colitis Patients
Lead Sponsor:
Tanta University
Conditions:
Microbiota
Probiotic Therapy
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to evaluate the role of microbiota and probiotics in Egyptian patients with ulcerative colitis.
Detailed Description
Inflammatory bowel disease (IBD) is a group of chronic diseases that significantly affects patients' quality of life and is mainly represented by Crohn's disease (CD) and ulcerative colitis (UC). The...
Eligibility Criteria
Inclusion
- Patients more than 18 years.
- Patients with ulcerative colitis in remission as assessed by the clinical activity index (CAI) ≤ 4, endoscopic index (EI) ≤ 4, and no signs of acute inflammation on histological examination.
Exclusion
- Active ulcerative colitis.
- Cardiac, hepatic, or renal disease.
- Pregnancy.
- History of major colonic surgery.
- Patients with any malignancy.
- Previously taking other probiotics.
- Use of steroids within the last 4 weeks before study entry.
- Use of antibiotics within the last 2 weeks before study entry
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2024
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT07180186
Start Date
January 1 2022
End Date
May 1 2024
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527